Clinical Trial Update: A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CFZ533 for Graves' Disease has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Disease

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graves' Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-05-21